Traduction de «breast screening most women » (Français → Néerlandais) :

At the breast screening Most women are nervous, but are not anxious or depressed. Gerard et al. Women from UK aged 40-64
Gerard et al. Women from UK aged 40-64 (1999) 83 EQ-5D years (eligible for screening) UK tariffs (general population) True negative 0.940 At the breast screening Most women are nervous, but are not anxious or depressed. clinic

17. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.
16. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.

12. Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?
11. Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Table 11: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 22 Study ID study
Table 9: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 21 Study ID study

56. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.
57. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.

13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.